Search
Now showing items 1-10 of 10
Evaluation of prognostic factors associated with differentiated thyroid carcinoma with pulmonary metastasis
(2016)
Background: Because one of the major sites for metastasis of thyroid cancers is the lung, studying the pattern of pulmonary metastasis may provide useful information for the effective treatment of these patients. In this ...
99 mTc-MIBI washout as a complementary factor in the evaluation of idiopathic dilated cardiomyopathy (IDCM) using myocardial perfusion imaging
(2012)
Rapid technetium-99 m methoxyisobutylisonitrile (99 mTc-MIBI) washout has been shown to occur in impairedmyocardia. This study is based on the hypothesis that scintigraphy can be applied to calculate the myocardial 99 ...
Assessment of radioiodine clearance in patients with differentiated thyroid cancer
(2012)
Radioiodine (131I iodide) has long been a safe, effective and widely used treatment in the management of differentiated thyroid cancer (DTC). Concerns regarding stochastic radiogenic risks have led to regulatory criteria ...
Chromosome aberrations after high-dose 131I and 99mTc-MIBI administration using a micronucleus assay
(2010)
Objective: We evaluated the potential detrimental cytogenetic effects of 99mTc-methoxyisobutyl isonitrile (MIBI) and 131I on patients who were exposed to the radiopharmaceutics for cardiac imaging or thyroid cancer therapy, ...
Management of gastrointestinal complaints in differentiated thyroid cancer patients treated with 131I: Comparison of the efficacy of pantoprazole, metoclopra-mide, and ondansetron – a randomized clinical trial [Behandlung gastrointestinaler beschwerden unter 131I-therapie bei patienten mit differenzier-tem schilddrüsenkarzinom: Vergleich der wirksamkeit von pantoprazol, meto-clopramid und ondansetron – eine randomisierte klinische prüfung]
(2014)
Objective: To compare safety and efficacy of pantoprazol, metoclopramide, ondansetron, as compared to placebo, in controlling gastrointestinal (GI) complaints of thyroid cancer patients treated with I-131these patients. ...
Relation between clinical and laboratory parameters with radiation dose rates from patients receiving iodine-131 therapy for thyroid carcinoma
(2009)
Three days following administration of radioactive iodine in 38 patients, exposure rates such as dose rate close to the dress (D0), dose rate of dress at 1 m (D1), dose rate close to the bedsheet (B0), dose rate of bedsheet ...
Phase 2 study of a high dose of 186RE-HEDP for bone pain palliation in patients with widespread skeletal metastases
(2013)
186Re-1-hydroxyethylidene-1,1-diphosphonate (HEDP) is an attractive radiopharmaceutical for the treatment of bone pain arising from skeletal metastatic lesions. Currently, 186Re-HEDP is most commonly used in European ...
One size does not fit all: The merit of absorbed doses to the blood in 131i therapy for differentiated thyroid carcinoma
(2015)
The amount of 131I necessary for successful ablation in patients with differentiated thyroid cancer (DTC) is still subject to debate. This study investigates the relationship of the absorbed dose of radiation to the blood ...
Scintigraphic parameters with emphasis on perfusion appraisal in rest 99mTc-sestamibi SPECT in the recovery of myocardial function after thrombolytic therapy in patients with ST elevation myocardial infarction (STEMI)
(2011)
Introduction: This study was performed to determine the clinical application of rest 99mTc-sestamibi in the assessment of viability and functional improvement of the left ventricle (LV) myocardium in the post-thrombolytic ...
The utility and prognostic value of dipyridamole technetium-99m sestamibi myocardial perfusion imaging SPECT in predicting perioperative cardiac events following non-cardiac surgery
(2013)
Objective: A perioperative cardiac events is one of the most important medical concerns for both surgeons and patients. The purpose of the current study was to determine the prognostic value of myocardial perfusion imaging ...